1461098100-8cc66030-cf0d-44f3-aecb-7e17a654932d

1. An ultrasonic image processing apparatus for processing a plurality of signals obtained by scanning an object to be inspected with an ultrasonic beam and respectively representing pixel values of a plurality of pixels within an ultrasonic image, said apparatus comprising:
a morphology processing unit for processing the plurality of signals to reduce speckles appearing in the ultrasonic image; and
a digital scan converter for converting a scan format of the plurality of signals processed by said morphology processing unit;
wherein said morphology processing unit performs first signal processing on the plurality of signals while moving a mask area determined based on a structure element in morphology processing, said first signal processing including multiplying pixel values of a plurality of pixels within the mask area by a first group of weighting factors set depending on positions within the mask area, respectively, and converting a pixel value at a center of the mask area into a maximum value of the pixel values multiplied by the first group of weighting factors, and performs second signal processing on the plurality of signals subjected to the first signal processing while moving a mask area determined based on a structure element in morphology processing, said second signal processing including multiplying pixel values of a plurality of pixels within the mask area by a second group of weighting factors set depending on positions within the mask area, respectively, and converting a pixel value at a center of the mask area into a minimum value of the pixel values multiplied by the second group of weighting factors; and
wherein said first and second groups of weighting factors are set such that a value obtained by multiplying corresponding factors within the mask area in said first and second groups together becomes 1.
2. The ultrasonic image processing apparatus according to claim 1, wherein:
said first group of weighting factors are set smaller according as the positions are apart from the center of the mask area; and
said second group of weighting factors are set larger according as the positions are apart from the center of the mask area.
3. The ultrasonic image processing apparatus according to claim 1, wherein said first and second groups of weighting factors are set based on a frequency of ultrasonic waves to be transmitted.
4. The ultrasonic image processing apparatus according to claim 1, wherein said first and second groups of weighting factors are set based on a depth of the object represented in the ultrasonic image.
5. The ultrasonic image processing apparatus according to claim 1, wherein said first and second groups of weighting factors are set based on a target part of observation.
6. The ultrasonic image processing apparatus according to claim 1, wherein said plurality of signals are obtained by scanning the object by using an ultrasonic endoscope being inserted into the object.
7. The ultrasonic image processing apparatus according to claim 1, further comprising:
a switch for switching whether reduction of speckles by said morphology processing unit is performed or not based on information inputted by a user.
8. An ultrasonic image processing method of processing a plurality of signals obtained by scanning an object to be inspected with an ultrasonic beam and respectively representing pixel values of a plurality of pixels within an ultrasonic image, said method comprising the steps of:
(a) processing the plurality of signals to reduce speckles appearing in the ultrasonic image; and
(b) converting a scan format of the plurality of signals processed at step (a);
wherein step (a) includes (i) performing first signal processing on the plurality of signals while moving a mask area determined based on a structure element in morphology processing, said first signal processing including multiplying pixel values of a plurality of pixels within the mask area by a first group of weighting factors set depending on positions within the mask area, respectively, and converting a pixel value at a center of the mask area into a maximum value of the pixel values multiplied by the first group of weighting factors, and (ii) performing second signal processing on the plurality of signals subjected to the first signal processing while moving a mask area determined based on a structure element in morphology processing, said second signal processing including multiplying pixel values of a plurality of pixels within the mask area by a second group of weighting factors set depending on positions within the mask area, respectively, and converting a pixel value at a center of the mask area into a minimum value of the pixel values multiplied by the second group of weighting factors; and
wherein said first and second groups of weighting factors are set such that a value obtained by multiplying corresponding factors within the mask area in said first and second groups together becomes 1.
9. The ultrasonic image processing method according to claim 8, wherein:
said first group of weighting factors are set smaller according as the positions are apart from the center of the mask area; and
said second group of weighting factors are set larger according as the positions are apart from the center of the mask area.
10. The ultrasonic image processing method according to claim 8, wherein said first and second groups of weighting factors are set based on a frequency of ultrasonic waves to be transmitted.
11. The ultrasonic image processing method according to claim 8, wherein said first and second groups of weighting factors are set based on a depth of the object represented in the ultrasonic image.
12. The ultrasonic image processing method according to claim 8, wherein said first and second groups of weighting factors are set based on a target part of observation.
13. An ultrasonic image processing program, embodied in non-transitory form on a computer readable medium, for processing a plurality of signals obtained by scanning an object to be inspected with an ultrasonic beam and respectively representing pixel values of a plurality of pixels within an ultrasonic image, said program allowing a CPU to execute the procedures of:
(a) processing the plurality of signals to reduce speckles appearing in the ultrasonic image; and
(b) converting a scan format of the plurality of signals processed at procedure (a);
wherein procedure (a) includes (i) performing first signal processing on the plurality of signals while moving a mask area determined based on a structure element in morphology processing, said first signal processing including multiplying pixel values of a plurality of pixels within the mask area by a first group of weighting factors set depending on positions within the mask area, respectively, and converting a pixel value at a center of the mask area into a maximum value of the pixel values multiplied by the first group of weighting factors, and (ii) performing second signal processing on the plurality of signals subjected to the first signal processing while moving a mask area determined based on a structure element in morphology processing, said second signal processing including multiplying pixel values of a plurality of pixels within the mask area by a second group of weighting factors set depending on positions within the mask area, respectively, and converting a pixel value at a center of the mask area into a minimum value of the pixel values multiplied by the second group of weighting factors; and
wherein said first and second groups of weighting factors are set such that a value obtained by multiplying corresponding factors within the mask area in said first and second groups together becomes 1.
14. The ultrasonic image processing program according to claim 13, wherein:
said first group of weighting factors are set smaller according as the positions are apart from the center of the mask area; and
said second group of weighting factors are set larger according as the positions are apart from the center of the mask area.
15. The ultrasonic image processing program according to claim 13, wherein said first and second groups of weighting factors are set based on a frequency of ultrasonic waves to be transmitted.
16. The ultrasonic image processing program according to claim 13, wherein said first and second groups of weighting factors are set based on a depth of the object represented in the ultrasonic image.
17. The ultrasonic image processing program according to claim 13, wherein said first and second groups of weighting factors are set based on a target part of observation.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A data transmission system comprising:
(i) a remote computer including
(a) a far end modem,
(b) a display providing a visual indication of a downstream data rate received and an upstream data rate transmitted by said data modem, and
(c) a browser providing a user interface with a remote network; and
(ii) a transmission facility connecting said modem to a central facility;

said central facility including:
(a) a local modem,
(b) a packet switch connected to said local modern so as to provide therethrough bidirectional digital communications with said remote computer, and
(c) a test server connected to said packet switch and configured to transmit and receive respective predetermined downstream and upstream messages to and from said remote computer, said test server including multiple sets of input parameters each set optimized for testing a particular speed of data communication service, said test server further configured to download executable code corresponding to a selected one of said sets of input parameters, said executable code including an applet to said remote computer, said applet executed by said remote computer for providing said visual indication of said downstream and upstream data rates wherein said visual indication of said downstream and upstream data rates is calculated based on transmissions of said predetermined downstream and upstream messages, said remote computer transmitting an indication of said downstream and upstream data rates to said test server for storage thereon.
2. The data transmission system according to claim 1 further including a bidirectional interface with a remote data network connected to said packet switch, said data transmission system selectively providing communication between said remote computer and (i) said test server and (ii) said remote data network.
3. The system according to claim 1 wherein said test server is further configured to receive packets from said remote computer and, in response, calculate a data rate.
4. The system according to claim 1 wherein said remote computer is programmed to calculate said downstream and upstream data rates independently of each other.
5. The system according to claim 1 wherein said far end modem comprises an asymmetric digital subscriber line (ADSL) terminal unit\u2014remote (ATU-R).
6. The system according to claim 1 wherein said transmission facility comprises twisted-pair.
7. The system according to claim 1 wherein said transmission facility comprises a subscriber line interface circuit (SLIC).
8. The system according to claim 1 wherein said transmission facility comprises a digital loop carrier subscriber line interface circuit (DLC-SLIC).
9. The system according to claim 1 wherein said central facility comprises a central office.
10. The system according to claim 1 wherein said central facility comprises a remote telecommunication equipment center.
11. The system according to claim 1 wherein said local modem comprises a digital subscriber line access multiplexer (DSLAM).
12. The system according to claim 11 wherein said DSLAM comprises an ADSL terminal unit\u2014central office (ATU-C).
13. The system according to claim 12 wherein said DSLAM further comprises a splitter configured to receive from said transmission facility a composite signal including said bidirectional digital communications and a telephony signal and separately provide said bidirectional digital communications and said telephony signal.
14. The system according to claim 1 wherein said packet switch comprises an ATM (asynchronous transfer mode) dedicated-connection switch.
15. The system according to claim 1 wherein said packet switch comprises a fast packet switching device.
16. The system according to claim 1 wherein said packet switch comprises one of a (i) frame relay, (ii) SMDS (switched multimegabit data service), (iii) switched Ethernet switch, and (iv) ATM.
17. The system according to claim 1 further comprising a router selectively connecting said packet switch to (i) said test server and (ii) a remote data network.
18. The system according to claim 17 wherein said router provides connectivity with a plurality of high speed data networks.
19. A data transmission network comprising:
(i) a plurality of remote computers, each including
(a) a far end modem, and
(b) a display capable of providing a visual indication of a downstream data rate received and an upstream data rate transmitted by said data modem;
(ii) a transmission facility connecting each of said modems to (iii) a central office facility;

said central office facility including:
(a) a plurality of local modems in communication with corresponding ones of said far end modems,
(b) a packet switch connected to said local modems so as to provide bi-directional digital data communications therethrough between said remote computers and at least one remote data network, and
(c) a test server connected to said packet switch including multiple sets of input parameters each set optimized for testing a particular speed of data communication service and configured to (i) selectively transmit to selective ones of said remote computers executable code corresponding to selective ones of said sets of input parameters, said executable code including an applet; and to transmit and receive respective predetermined downstream and upstream messages to and from selective ones of said remote computers,
wherein said visual indication of said downstream and upstream data rates is calculated based on transmissions of said predetermined downstream and upstream messages, at least one of said remote computers being programmed in response to said applet to (1) calculate said downstream and upstream data rates independently of each other, and said test server configured to download executable code to said selective ones of said remote computers for providing said visual indication of said downstream and upstream data rates and (2) transmit an indication of said downstream and upstream data rates to said test server for storage thereon.
20. The data transmission system according to claim 19 further including a bidirectional interface with a remote data network connected to said packet switch, said data transmission system selectively providing communication between said remote computers and (i) said test server and (ii) said remote data network.
21. The data transmission network according to claim 19 wherein said test server is further configured to receive packets from said selective ones of said remote computers said predetermined upstream message received from said selective ones of said remote computers and, in response, calculate respective data rates.
22. The data transmission network according to claim 19 wherein at least one of said remote computers is programmed to calculate said downstream and upstream data rates independently of each other.
23. The data transmission network according to claim 19 wherein at least one of said far end modems comprises an ADSL ATU-R.
24. The data transmission network according to claim 19 wherein said transmission facility comprises twisted-pair.
25. The data transmission network according to claim 19 wherein said transmission facility comprises an SLIC.
26. The data transmission network according to claim 19 wherein said transmission facility comprises a DLC-SLIC.
27. The data transmission network according to claim 19 wherein said central office facility further comprises a voice switch wherein telephone signals and said bi-directional digital data communications are transmitted by said transmission facility and said voice switch is connected to said transmission facility to receive said telephone signals.
28. The data transmission network according to claim 19 wherein said central facility comprises a remote telecommunication equipment center.
29. The data transmission network according to claim 19 wherein said local modem comprises a DSLAM.
30. The data transmission network according to claim 29 wherein said DSLAM comprises an ADSL ATU-C.
31. The data transmission network according to claim 30 wherein said DSLAM further comprises a splitter configured to receive from said transmission facility a composite signal including said bidirectional digital communications and a telephony signal and separately provide said bidirectional digital communications and said telephony signal.
32. The data transmission network according to claim 19 wherein said packet switch comprises an ATM (asynchronous transfer mode) dedicated-connection switch.
33. The data transmission network according to claim 19 wherein said packet switch comprises a fast packet switching device.
34. The data transmission network according to claim 19 wherein said packet switch comprises one of a (i) frame relay, (ii) SMDS, (iii) switched Ethernet switch, and (iv) ATM.
35. The data transmission network according to claim 19 further comprising a router selectively connecting said packet switch to (i) said test server and (ii) a remote data network.
36. The data transmission network according to claim 35 wherein said router provides connectivity with a plurality of high speed data networks.
37. A method of measuring a performance of a data transmission facility comprising the steps of:
connecting a remote data terminal device to a central communications facility with said data transmission facility;
rerouting, at said central communications facility, a data communication connection of said remote data terminal device with a remote data network in order to establish connectivity of said remote data terminal device with a test server;
downloading from said test server to said remote data terminal device a test program comprising executable code corresponding to a selected one of a plurality of sets of input parameters each set optimized for testing a particular speed of data communication service, said executable code including an applet;
transmitting from said remote data terminal device to said test server an upstream test signal;
transmitting from said test server to said data terminal device a downstream test signal;
providing, on said data terminal, a user interface with said test server including a browser;
executing said applet on said data terminal to provide an indication of upstream and downstream data rates;
displaying on said remote data terminal a performance of said data transmission facility in transmitting said upstream and downstream test signals including said upstream and downstream data rates, and
transmitting an indication of said downstream and upstream data rates to said test server for storage thereon.
38. The method according to claim 37 further comprising a step of receiving packets from said remote data terminal and, in response, calculating a data rate.
39. The method according to claim 37 further comprising steps of calculating data rates of said upstream and downstream test signals.
40. The method according to claim 37 wherein said data transmission facility comprises a pair of ADSL Terminal Units connected by a communications link.
41. The method according to claim 40 wherein said communications link comprises twisted-pair.
42. The method according to claim 40 wherein said communications link comprises an SLIC.
43. The method according to claim 40 wherein said communications link comprises a DLC-SLIC.
44. The method according to claim 40 further comprising the steps of:
combining a telephone signal with said upstream and downstream test signal to form a composite signal;
splitting said composite signal to separate said telephone, upstream and downstream test signal; and
providing said telephone signal to a voice switch and to a remote telephone terminal associated with said remote data terminal device.

1461098091-ecb2cb22-38be-4a24-a72e-2b16956f6ba5

1. A system for pumping liquid comprising:
two liquid columns for reaching a body of liquid at their bottom, each liquid column comprising a liquid level detector and a one-way valve allowing liquid to flow upward;
an upper conduit for sealably connecting to tops of the two liquid columns and comprising a sealable gas valve for extracting gas from the upper conduit;
an actuated conduit having ends connecting to each of the two liquid columns above their one-way valve, the actuated conduit comprising, at each end, a one-way valve allowing liquid to flow inward from each of the two columns, the actuated conduit further comprising, between its two one-way valves, a switched valve allowing liquid to flow out of the system from each one-way valve at a time; and
a controller connected to the liquid level detectors for controlling the switched valve, whereby:
extraction of a gas from the upper conduit raises liquid in each of the two liquid columns to a starting level,
as the gas valve is sealed, liquid from one of the liquid columns flows out of the system through the actuated conduit and through the switched valve; and
as the liquid level in the one of the liquid columns reaches a minimum level, the switched valve switches to allow liquid to flow from another one of the liquid columns.
2. The system of claim 1, comprising an output conduit connected to the switched valve for collecting liquid flowing out of the system.
3. The system of claim 2, comprising a turbine and a generator connected to the turbine, wherein liquid flowing out of the system through the output conduit actuates the turbine for producing electricity at the generator.
4. The system of claim 2, wherein liquid output from the output conduit is for an element selected from the group consisting of domestic, industrial and agricultural use.
5. The system of claim 1, comprising a buffer reservoir connected to the switched valve for collecting liquid flowing out of the system.
6. The system of claim 5, comprising a regulating valve connected to the buffer reservoir for regulating a flow of liquid out of the system.
7. The system of claim 6, wherein the regulating valve prevents liquid from flowing out of the system while gas is extracted from the upper conduit.
8. The system of claim 6, wherein the regulating valve and the buffer reservoir smooth out the flow of liquid out of the system.
9. The system of claim 1, wherein each one-way valve comprises a rubber ring for sealably connecting to an internal perimeter of one of the conduits or of one of the columns, and a ball located on one side of the rubber ring, the ball allowing a liquid flow when separated from the rubber ring, and preventing a liquid flow when mated with the rubber ring.
10. The system of claim 9, wherein the one-way valve further comprises a spring for maintaining the ball against the rubber ring in the absence of a liquid flow.
11. A balancing liquid pump, comprising:
a sealable gas-liquid balancing conduit;
two inlet conduits for connecting to a body of liquid at their bottom in unidirectional upward direction and for connecting to the gas-liquid balancing conduit at their top;
two unidirectional inward outlet conduits, each outlet conduit for connecting at one end to one of the inlet conduits and at another end to a common switched valve, the switched valve allowing liquid to flow out of the pump from one of the two inlet conduits at a time;
a starting system for initiating a flow of liquid from the body of liquid and for raising a level of liquid in at least one of the inlet conduits;
wherein as liquid flows out of the pump from one of the inlet conduits, a level of liquid in the one of the inlet conduits goes down, and gas in the gas-liquid balancing conduit follows the level of liquid in the one of the inlet conduit;
whereby movement of the gas in the gas-liquid balancing conduit pumps liquid from the body of liquid into another one of the inlet conduits.
12. The pump of claim 11, comprising liquid level detectors in each inlet conduit, wherein detection of a low liquid level in the one of the inlet conduits controls a change of position of the switched valve for blocking a liquid flow from the one of the inlet conduits and allowing liquid to flow out from the other one of the inlet conduits.
13. The pump of claim 12, comprising a controller connected to the liquid level detectors for controlling the starting system and the switched valve.
14. The pump of claim 11, wherein a liquid flow out of the pump is prevented during a starting phase.
15. The pump of claim 14, wherein the switched valve prevents a liquid flow out of the pump during the starting phase.
16. The pump of claim 11, wherein the starting system comprises a gas valve and a gas pump for extracting gas from the gas-liquid balancing conduit during a starting phase.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula (I):
andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein
R1 is independently chosen from hydrogen, halo, \u2014CN, \u2014OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, \u2014NH2, \u2014NH(C1-C4alkyl), and \u2014N(C1-C4alkyl)(C1-C4 alkyl);
R2 is aryl, or heteroaryl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl;
L is a bond, or optionally substituted C1-C6alkylene;
W is cycloalkyl, heterocycle, aryl, or heteroaryl;
R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, and optionally substituted aryl,
provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, and optionally substituted aryl;
R4 is C1-C6alkyl, C2-C6alkenyl, or C2-C6alkynyl, each of which is optionally substituted;
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, \u2014CN;
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O), NH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN;
Lx is a bond, or optionally substituted C1-C6alkylene;
m is 0, 1 or 2,
n is 1 or 2,
p is 1, 2 or 3.
2. (canceled)
3. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R1 is independently chosen from hydrogen, halo, \u2014CN, \u2014OH; or is chosen from methyl, ethyl, n-propyl, i-propyl, \u2014NH2, N-methylamino, N,N-dimethylamino, N-ethylamino, N-n-propylamino, N-i-propylamino, methoxy, ethoxy, propoxy, isopropoxy, each of which is optionally substituted.
4. (canceled)
5. (canceled)
6. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is C5-C10aryl, or 5-10 membered heteroaryl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted 5-10 membered heteroaryl, optionally substituted C5-C10 aryl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, \u2014CN;
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN.
7. The compound of claim 6, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is independently chosen from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, and, indanyl, indolinyl, indolin-2-one, 2,3-dihydrobenzofuryl, benzod1,3dioxolyl, and 1,2,3,4-tetrahydroquinolinyl, chroman, 2,3-dihydrobenzob1,4dioxinyl, 3,4-dihydro-2H-benzob1,4oxazinyl, isochroman, 1,3-dihydroisobenzofuryl, 1H-benzod1,3oxazin-2(4H)-onyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)NH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, \u2014CN;
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN.
8. The compound of claim 7, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is independently chosen from
each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and Wand R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN.
9. The compound of claim 8, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is independently chosen from
each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)NH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN.
10. (canceled)
11. (canceled)
12. The compound of claim 11, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein L is a bond, or \u2014CH2\u2014, or \u2014CH2\u2014CH2\u2014.
13. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein W is C3-C8cycloalkyl, 3-8 membered heterocycle, C5-C10aryl, or 5-10 membered heteroaryl.
14. The compound of claim 13, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein W is cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, phenyl, naphthyl pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, or quinolinyl.
15. (canceled)
16. The compound of claim 14, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein W is tetrahydrofuryl, tetrahydropyranyl, or morpholinyl.
17.-19. (canceled)
20. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted C3-C8cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted C5-C10aryl, and optionally substituted 5-10 membered heteroaryl, provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted C3-C8cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted C5-C10aryl, and optionally substituted 5-10 membered heteroaryl
R4 is optionally substituted C1-C4alkyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)NH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN;
Lx is a bond, or optionally substituted C1-C6 alkylene.
21. The compound of claim 20, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), or selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, phenyl, naphthyl pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, and quinolinyl, each of which is optionally substituted, provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O),
R4 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, each of which is optionally substituted
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)NH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)1NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN;
Lx is a bond, or optionally substituted C1-C4alkylene.
22. (canceled)
23. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, C1-C4alkyl, C3-C8cycloalkyl, C5-C10aryl, 5-10 membered heteroaryl, and 3-8 membered heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C1 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C1 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN.
24. (canceled)
25. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C1 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN.
26. (canceled)
27. (canceled)
28. The compound of formula (I) according to claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein
R1 is independently chosen from hydrogen, halo, \u2014CN, \u2014OH; or is chosen from methyl, ethyl, n-propyl, i-propyl, \u2014NH2, N-methylamino, N,N-dimethylamino, N-ethylamino, N-n-propylamino, N-i-propylamino, methoxy, ethoxy, propoxy, isopropoxy, each of which is optionally substituted,
R2 is independently chosen from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, and, indanyl, indolinyl, indolin-2-one, 2,3-dihydrobenzofuryl, benzod1,3dioxolyl, and 1,2,3,4-tetrahydroquinolinyl, chroman, 2,3-dihydrobenzob1,4dioxinyl, 3,4-dihydro-2H-benzob1,4oxazinyl, isochroman, 1,3-dihydroisobenzofuryl, 1H-benzod1,3oxazin-2(4H)-onyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
L is a bond, or optionally substituted C1-C6 alkylene,
W is cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, phenyl, naphthyl pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, or quinolinyl,
R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, and oxo(\u2550O), provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)17NR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O),
R4 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, each of which is optionally substituted,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, and oxazepanyl, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)1NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN,
Lx is a bond, or optionally substituted C1-C4alkylene,
m is 0, 1 or 2,
n is 1 or 2,
p is 1, 2 or 3.
29. (canceled)
30. The compound of claim 1, chosen from compounds 1 to 323 andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof.
31. A composition comprising the compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof and at least one pharmaceutically acceptable carrier.
32.-34. (canceled)
35. A method for inhibiting a Syk kinase, comprising administering to a system or a subject in need thereof a therapeutically effective amount of a compound of Formula (I) of claim 1.
36. A method for treating a Syk-mediated disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) of claim 1.
37. (canceled)
38. The method of claim 36, wherein the disease is allergic asthma, allergic rhinitis, rheumatoid arthritis, multiple sclerosis, lupus, systemic lupus erythematosus, lymphoma, B cell lymphoma, T cell lymphoma, leukemia, myelodysplasic syndrome, anemia, leucopenia, neutropenia, thrombocytopenia, granuloctopenia, pancytoia or idiopathic thrombocytopenic purpura.
39. (canceled)